All posts by Ciara Jackson

Aptar Pharma Co-Organizes the Third Edition of RDD Asia® in Kera...

Aptar Pharma is pleased to announce the co-organization and its diamond sponsorship of the third Respiratory Drug Delivery (RDD®) Asia scientific conference, which will take place at the Grand Hyatt Kochi hotel from November 14-16 in Kerala, India.

In addition to co-organizing the conference and exhibiting, Aptar Pharma will host an interactive workshop on Thursday, November 15 addressing the most recent FDA guidance on Combination Products, with a focus on respiratory and nasal drug products. The seminar, entitled “Decoding FDA’s Recent Combination Drug Product Guidance: Applications to DPIs, pMDIs, and Nasal Sprays,” will be presented by Badre Hammond, Associate Director, Market Development at Aptar Pharma. This workshop, which will be repeated three times during the day, will give insights into optimal approaches to help secure approval in this changing and challenging regulatory landscape. It will review various topics, including the definition of combination products, NDA/ANDA submissions, regulatory pathway review, Human Factor studies in the context of combination products, and clarify expectations on the sponsor, the device supplier and regulators.

Furthermore, Dr. Gerallt Williams, Director of Scientific Affairs at Aptar Pharma, will present a poster entitled “Interpretation Of Manual Actuation Profiles From Nasal Bi-dose Spray Devices”, which demonstrates their impact on analytical and regulatory requirements.

Building on the successes of previous RDD conferences in the U.S., Europe and Asia, RDD Asia 2018 is recognized as one of the premium international meetings in the area. More than 200 delegates from Asia and beyond are expected to attend.

To connect with Aptar Pharma at RDD Asia 2018 and meet their team of experts, register at:

Click here to download our full Press Release.


November 5, 2018

Aptar Pharma QuickStart™, an injectable device development kit,...

Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart™ for injectable drug development at CPhI Worldwide 2018, in Madrid, Spain, October 9th.

Aptar Pharma QuickStart™ is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, QuickStart™ provides everything needed for the small volume filling of high value formulations. Also included in the kit are all the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components. Co-developed alongside Schott and EMA Pharmaceuticals, Aptar Pharma QuickStart™ is available to cater to different sizes and configurations of vials, stoppers and caps.

Aptar Pharma’s proven expertise in device development and formulation helps ensure that QuickStart™’s components satisfy all regulatory requirements, allowing users to access commercial scale quality at a development stage cost.

CPhI Worldwide, which takes place October 9-11, 2018 at IFEMA, Feria de Madrid, will welcome more than 45,000 pharma professionals, which provides a prime opportunity to demonstrate the value of Aptar Pharma QuickStart™ to prospective partners.

To read full Press Release, click here.

October 9, 2018

Aptar Pharma Launches PureHale, a New Portable and Ready-to-Use U...

Aptar Pharma continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

With the ongoing rise in pollution, which is a major environmental risk to health, the need for upper respiratory relief is more prominent than ever. Utilizing Aptar Pharma’s well-established Bag-on-Valve system, PureHale’s innovative technology distributes a continuous fine mist (20-30µm) that gently cleanses, moisturizes and soothes the upper respiratory tract. When used in combination with a customer’s formulation, it could help to reduce irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues.

PureHale’s portability allows consumers to relieve their symptoms wherever and whenever needed. Unlike traditional nebulizers, the PureHale system does not require batteries or the prefilling of a reservoir and does not need to be plugged in or charged. The PureHale technology platform is quieter and lighter than traditional nebulizers, is easy-to-use and includes mask and mouthpiece options, offering adaptable treatment and suitable for family use.

Guenter Nadler, Director Business Development at Aptar Pharma said of this latest launch, “We are really excited to announce this newest Aptar Pharma innovation. We have seen a real need for a device of this kind – traditional nebulizers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time. Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulization and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”

PureHale will be officially launched at CPhI Worldwide in Madrid on October 9th at Booth 4D10 and is a finalist in the CPhI Pharma Awards in the Excellence in Pharma: Drug Delivery Device category.

Click here for full the Press Release.


October 2, 2018

Aptar Pharma to Showcase Our Latest Offerings at PDA PFS, Orlando...

Aptar Pharma is pleased to be exhibiting at 2018 PDA Universe of Pre-Filled Syringes and Injection Devices (PDA PFS), taking place October 8-9, 2018 in Orlando, Florida.

At our Booth No. 601 we will be showcasing the latest developments in our Premium offering and PFS product portfolio.

Our expert team will be presenting the following posters at PDA PFS entitled:

“Migration Study to Evaluate the Impact of Steam vs. Gamma Irradiation in Ready-To-Use (RTU) Uncoated Stoppers and Fluorinated (ETFE) Film Coated Stoppers” presented by Michael J. Mayer, Senior Scientist from Next Breath, a specialty company of Aptar Pharma.

“Establishing a Market Leading Answer to a Reduced Particulates Profile for Elastomeric Solution” presented by Arnaud Fournier, Senior Business Project Manager, Aptar Pharma.

Aptar Pharma will also moderate a session during PDA PFS. Taking place on Monday, October 8 from 1.30 p.m. to 3 p.m., the session entitled ‘B1: When Packaging Becomes More than Packaging’, will be moderated by Joel Cotten, Business Development Director, Aptar Pharma, and will discuss, from a high-level perspective, how packaging must protect injectable drugs as well as the intermediate injection systems until they reach the final users. Some of the most recent innovations in the market that could change the future of the injectable packaging offering will also be discussed.

For more details on this session, please click here.

September 25, 2018

Aptar Pharma to launch PureHale and showcase its portfolio of con...

Aptar Pharma, a leading drug delivery systems provider, is pleased to showcase its commitment to meeting new market trends at CPhI Worldwide this year. The world’s largest pharma trade show, held 9 – 11 October in Madrid, will see more than 100,000 pharmaceutical professionals coming together for exhibitions, conferences and online communities, and this year Aptar Pharma will be showcasing an industry first with its PureHale device – a new portable drug delivery device designed for upper respiratory care – at stand 4D10.

In addition to PureHale, AptarPharma will also reveal:

  • A range of new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes
  • A portfolio of gamma-sterilized drug delivery components to reduce bioburden
  • Aptar Pharma’s Support Services initiative, a portfolio of stage-specific development packages to help customers in their journey from molecule to market

Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the-counter treatments.

Furthermore, Aptar Pharma executives will be delivering three Pharma Insight Briefings outlining the latest trends, technology and product innovations:

“Debunking the leachable myths of gamma sterilization: A migration study of steam vs gamma” – Julie D. Suman, R.Ph., Ph.D., President of Next Breath, a division of Aptar Pharma. Tuesday, 9 October, 11:50-12:20.

“Portable care for your respiratory tract: Exploring new technology platforms” – Guenter Nadler, Director Business Development, Aptar Pharma. Tuesday, 9 October, 12:30-13:00.

“Building a connected devices eco-system for digital medicines” – Sai Shankar, Director Business Development, Aptar Pharma. Wednesday, 10 October, 13:50-14:20.

Aptar Pharma’s team of experts will be on hand at our booth 4D10 to explain and demonstrate their latest drug delivery technologies and to discuss ways they can partner with customers to ensure their drug delivery challenges are met.

For more information about Aptar Pharma’s presence at CPhI Worldwide 2018, please click here to view the full press release.

September 17, 2018

Join Aptar Pharma’s Live Webinar “Decoding the FDA’s Recent...

On September 18, 2018, Aptar Pharma will host a live webinar to provide insight into how the FDA’s 2018 guidance affects future Combination Product submissions for respiratory and nasal drug products, specifically DPIs, pMDIs, and Nasal Sprays.

Aimed at professionals working in drug development, packaging, business development, CMC and regulatory affairs, this free webinar will be hosted by Aptar Pharma’s Wendy Bolf, Regulatory Affairs Manager and Badre Hammond, Associate Director, Market Development, and will offer guidance on optimal approaches to help secure approval in this changing and challenging regulatory landscape.

The following key topics will be covered:

  • The Basics – medical device, combination product, and packaging components
  • NDA/ANDA submissions: regulatory pathway review for Combination Products
  • Human Factor studies in the context of Combination Products
  • Clarifying expectations: Sponsor, device supplier and regulators

“Decoding the FDA’s Recent Combination Drug Product Guidance: Applications to DPIs, pMDIs and Nasal Sprays” takes place on September 18, 2018 at 15.00 GMT/10.00 EST

Register now for Aptar Pharma’s webinar by clicking here. 

August 27, 2018

Aptar Pharma’s Preservative-Free Multidose Dispenser Approved f...

Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been announced as the approved delivery device for Bausch+Lomb’s Levofree Multidose in France.  This marks the first approval by the French National Agency for Medicines and Health Products Safety (ANSM) for Aptar Pharma’s Ophthalmic Dispenser.

Aptar Pharma has been working closely with Bausch+Lomb, one of the world’s leading Eye Care companies, to achieve this first ANSM approval of an Eye Care product in its multidose device. The approval has further expanded the regulatory acceptance of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for preservative-free Eye Care formulations.

With more than 150 commercial references worldwide, Aptar Pharma’s Ophthalmic Squeeze Dispenser meets key industry and patient needs for Eye Care by delivering improved patient safety, accurate design and product integrity. The ergonomic intuitiveness of the squeezable container with a low actuation force contributes to the high levels of acceptance. The Eye Care delivery solution is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions, while it is also the first and only FDA-reviewed delivery system for multidose, preservative-free Eye Care products.

“Our Ophthalmic Dispenser technology has been a great success for our customers,” explained Matthias Birkhoff, Vice President Business Development, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the French ANSM with confidence.”

For full details, download our press release here.

June 25, 2018

Aptar Pharma and Propeller Health Discuss the Four Keys to Succes...

Aptar Pharma is co-featured with partner Propeller Health in this month’s special issue of ONdrugDelivery magazine, which focuses on Connecting Drug Delivery.

Entitled ‘Connected Medicine: Insights from Payers and Other Stakeholders’ and written by Sai Shankar, Director, Business Development – Connected Devices at Aptar Pharma and Chris Hogg, Chief Operating Officer of Propeller Health, the feature identifies four key themes for ensuring the promise of connected devices is successfully met.

The experts explain how addressing Connectivity & Patient Engagement, Adherence, Coverage and Cost & Adoption Challenges are crucial to the success of connected medicine. The article authors also discuss new research and their recent experiences in digital health, including interviews with payers to explore the current state of connected medicines.

Read the full article here.





June 20, 2018

Aptar Pharma Discusses Injectable Drug Delivery Partnering Consid...

 Once again putting forth its expertise in Injectable drug delivery, Aptar Pharma is featured in the May edition of ONdrugDelivery magazine.

Entitled ‘Pharma Partnering Considerations for Injection Device Components’, this Expert View piece explores the key considerations Pharma companies should take into account for choosing the best possible partner to deliver and manufacture premium injectable components.

Written by Adam Shain, Director, Global Business Development, Injectables at Aptar Pharma, the feature highlights requirements that manufacturing partners should comply with to ensure that the resulting partnership will be symbiotic, mutually beneficial and ultimately deliver superior outcomes. Such requirements include quality assurance, consistency of supply and the sterilization of components.

Read the full article here:

June 7, 2018

Aptar Pharma to Unveil Innovative Inhalation Drug Delivery Soluti...

Aptar Pharma is pleased to be exhibiting once again at CPhI China 2018, from June 20-22 at the Shanghai New International Exhibition Center, Shanghai, China.

At Booth No. N5F30, we will be introducing new market innovations in inhalation drug delivery for the Chinese market, with our experts on hand to demonstrate the benefits of these exciting respiratory solutions designed to help fight the effects of air pollution.

We will also be showcasing Aptar Pharma’s Bag on Valve (BOV) technology as well as our wide range of advanced preservative-free dispensing systems for dermal, eye care and nasal drug delivery routes, which offer pharmaceutical professionals flexibility and performance when dealing with formulation challenges in the industry today.

An innovation wall at the booth will provide visitors with the opportunity to discover a wide range of Aptar Pharma’s technological innovations, such as PremiumCoat™, the coated stopper that represents a step change in the provision of elastomeric stoppers and offers a reduction in particulates for injectables drug delivery.

Further to exhibiting, we are proud to be hosting a half-day seminar on Friday morning, June 22 from 9.30-11.30am, where two of our Aptar Pharma experts will present the following interactive sessions:

  • ‘Healthy Nose, Healthy Life: A Glance at Global Successful Products for Upper Respiratory Health’ with Guenter Nadler, Director Business Development, Consumer Health Care Division. 9.30-10.30am
  • ‘Say No to Preservatives: Package Innovation for Ophthalmic & Dermal Products’ with Tianjiao Fu, Business Development Manager China, Pharma Sales. 10.30-11.10am

A Q&A session will follow.  The seminar will take place at location N8 in Meeting Room D.

To connect with Aptar Pharma and meet our experts, register for CPhI China today:

Aptar Pharma looks forward to seeing you there!


May 25, 2018

Aptar Pharma to Showcase Diverse Portfolio of Drug Delivery Solut...

Aptar Pharma is pleased to exhibit once again at FCE Pharma, which will be held from May 22-24, 2018 at the São Paulo Expo, São Paulo, Brazil.  Aptar Pharma has been a main exhibitor at this major event and looks forward to another successful presence at this year’s show.

At Booth No. H021, our experts will present Aptar Pharma’s diverse portfolio of drug delivery solutions and technology innovations across nasal, pulmonary, eye care, dermal and injectable routes.

A highlight of this year’s showcase will be Aptar Pharma’s Ophthalmic Squeeze Dispenser (OSD). With growing customer interest in the Latin America market for preservative free formulations, our eye care experts will be on hand to highlight the benefits of this multi-dose dispenser for preservative-free ophthalmic preparations. With over 150 references worldwide, the Aptar Pharma Ophthalmic Squeeze Dispenser is the first and only FDA-reviewed preservative free dispensing technology and is suitable for a wide range of viscosities.

With almost 17,000 visitors, FCE is the key pharmaceutical and cosmetics tradeshow in Latin America, and is an annual networking place for all the major players in the pharmaceutical industry.

Aptar Pharma has a strong presence in Latin America, with several offices in Brazil and Argentina, and a fully dedicated manufacturing site in Varela, Argentina.

Be sure to visit Aptar Pharma at Booth No. H021 at FCE Pharma this year. Discover our innovative drug delivery solutions portfolio and see why Aptar Pharma is your trusted partner not only in Latin America, but also worldwide.

Aptar Pharma Discusses the Benefits of Drug Repurposing in April ...

Aptar Pharma is featured in the April edition of ONdrugDelivery magazine, which focuses this month on Pulmonary & Nasal Drug Delivery.

Entitled “Drug Repurposing – Broadening Patient Accessibility Via a Change in Drug Delivery System”, the feature lays out the major benefits of drug repurposing for both the patient and pharmaceutical customer. Drug Repurposing is the application whereby an existing drug product is reformulated for a new route of administration and/or therapeutic area, providing major benefits for both the patient and the pharmaceutical customer.

Written by three of our Aptar Pharma experts, Badre Hammond – Associate Director, Market Development, Gerallt Williams, PhD – Director, Scientific Affairs and Herve Pacaud – Business Development Director, the article explains why the majority of drug repurposing projects we have participated in so far have resulted in a nasal device being the administration route of choice.

Read the full article here

April 19, 2018

Aptar Pharma to Exhibit Eye Care Packaging Innovations at ARVO An...

Aptar Pharma, a leading provider of innovative drug delivery systems, is delighted to be presenting at the ARVO Annual Meeting 2018, taking place on April 29 – May 3 at the Hawaii Convention Center, Honolulu, Hawaii.

ARVO’s annual international conference brings together eye and vision researchers to provide the public, patients and policymakers with insight into how their sight-saving work greatly benefits society.

With over 150 references for both prescription medications and consumer products, Aptar Pharma will exhibit at Booth No. 827, where we will demonstrate our expertise in the field of multi-dose preservative-free packaging for Eye Care to ARVO’s 11,000 expected delegates. There will be a special focus on our versatile Ophthalmic Squeeze Dispenser Technology Platform, which allows for a wide range of configurations and applications, enabling customized solutions for specific ophthalmic formulations. With Aptar Pharma known for creating the first and only FDA-reviewed preservative free dispensing technology, our experts will provide delegates with insight into how we can accelerate customers’ speed-to-market in line with industry standards.

Matthias Birkhoff, Vice President Business Development, Global Market Development Consumer Health Care, Aptar Pharma, will present a talk on May 1 at 1pm entitled ‘Trends and Technologies in Ophthalmic Drug Delivery – Significance of Microbiological Safety and Intuitive Design’. The talk will be held at Booth 1800 in the Exhibit Hall.

To connect with Aptar Pharma and meet our team of experts, register for ARVO today:

April 17, 2018

Aptar Pharma to Showcase New Market Innovations at Interphex 2018...

Aptar Pharma, a leading provider of innovative drug delivery systems, is pleased to exhibit our recent advancements at two upcoming Pharma events during April – Interphex 2018, New York City, April 17-19 and CPhI North America 2018, Philadelphia, April 24-26.

At both shows, Aptar Pharma will highlight the benefits of our state-of-the-art manufacturing facility expansion in Congers, New York. Find out from our experts how we have broadened our capabilities to continue to deliver solutions to your drug delivery challenges with a greater manufacturing presence in North America. Equipped with the latest technologies to meet growing quality requirements for regulated markets, our expanded site further supports Aptar Pharma’s extensive drug delivery solutions, including our Premium portfolio of injectable components.

CPhI North America

At our Aptar Pharma Booth No. 2104 at CPhI North America 2018, attendees will have the exclusive opportunity to discover more about an upcoming market innovation within Aptar Pharma’s Consumer Health Care portfolio. Our experts will be on hand to discuss this new enhancement to our Drug Delivery Systems range. Be one of the first to stop by to find out how our new technologies and features can support your drug formulation or consumer product.

Latitude®, Aptar Pharma’s novel side-actuated nasal spray device, will also be a highlighted innovation at CPhI North America. Designed to help improve patient ease-of-use and compliance with its ergonomics and intuitiveness, Latitude® is suitable for a wide range of patient applications, including self-administration and pediatrics. Learn from our experts at CPhI North America how we can support your brand differentiation.

CPhI North America 2018, which takes place from April 24-26, 2018 at the Pennsylvania Convention Center, Philadelphia, PA, USA connects 7,400 pharmaceutical professionals with the opportunity to network, source partners and learn about new trends and technologies across the entire supply chain.

Join us at Booth No. 2104, in the InnoPack Packaging Zone. For more information on CPhI North America, please visit

Interphex 2018

At Interphex 2018, Booth No. 1734, our Aptar Pharma experts will showcase our single shot nasal drug delivery device, Unit Dose System (UDS). UDS was designed to enable the systemic delivery of drugs without the need for injection or administration by a healthcare professional. Come and learn from our experts how Aptar Pharma can help you make a positive impact on patients’ lives with UDS – the delivery device for NARCAN®, the first and only FDA-approved nasal form of Naloxone used for the treatment of an opioid emergency.

Our Eye Care experts will demonstrate the benefits of Aptar Pharma’s Ophthalmic Squeeze Dispenser (OSD), the multidose dispenser for preservative-free ophthalmic preparations suitable for a wide range of viscosities. Talk to us at Interphex about how the OSD can enhance your formulation delivery.

Interphex 2018 takes place from April 17-19 at the Javits Center in New York City. As the premier pharmaceutical, biotechnology and medical device development and manufacturing exhibition, Interphex brings together like-minded professionals to share insights, knowledge and technology innovations.

Find Aptar Pharma at Booth No. 1734. Visit for more information.

April 11, 2018

Aptar Pharma to Showcase Next Generation of Integrated Connected Devices at RDD 2018 Arizona

Aptar Pharma, a leading provider of innovative drug delivery systems, is delighted to be a Platinum Sponsor at RDD 2018, taking place from April 22-April 26 at the JW Marriott Starr Pass Resort and Spa in Tucson, Arizona.

 The RDD conference series is recognized as one of the premier international meetings in the respiratory field, impacting regulatory and scientific policies worldwide. RDD brings together pharmaceutical experts within the medical aerosol community to share innovative research, technology and services of interest.

As part of the Platinum Sponsor Seminars at RDD 2018, two Aptar Pharma experts will present a 40-minute talk on the most recent FDA guidance on Combination Products, and will focus specifically on respiratory and nasal drug products.

The seminar, entitled “Decoding FDA’s Recent Combination Drug Product Guidance: Applications to DPIs, pMDIs, and Nasal Sprays” will be presented by Badre Hammond, Associate Director, Market Development Aptar Pharma Prescription and Wendy Bolf, Regulatory Affairs Manager, Aptar Pharma Prescription.

Aptar Pharma’s Platinum Sponsor Seminar will take place twice on Tuesday, April 24, in Tucson Room I and J, at 8:00 AM and again at 8:45 AM.

Aptar Pharma will host an interactive table, located in the Arizona Ballroom of the JW Marriott Starr Pass Resort and Spa, where our team of experts will showcase our innovative range of MDIs, DPIs and BAIs, demonstrating how they can accelerate speed-to-market by assisting customers from concept to regulatory submission and approval. There will also be a Connectivity Focus, dedicated to the growing field of c-Devices, offering insight into our range of add-on and integrated c-Devices.

Connect with Aptar Pharma and register for RDD 2018 today! Simply visit:

For further information, please click here to view the full press release.

Aptar Pharma to Exhibit Latest Injectable Developments at 2018 PD...

Aptar Pharma, a leading provider of innovative drug delivery systems, is pleased to once again be an exhibitor at the 2018 PDA Annual Meeting, taking place on March 19-21 in Orlando, Florida.

The 2018 PDA Annual Meeting presents pharma professionals with the opportunity to gain unique insights into industry advancements in processing, manufacturing and quality control, as well as developments for new pharmaceutical and biopharmaceutical products. Delegates also have access to plenary sessions focused on future trends, disruptive technologies and patient centricity.

Aptar Pharma experts will showcase the latest developments in its Premium product portfolio of PremiumFill®, PremiumCoat™ and PremiumVision™ at Stand No. 406, demonstrating its response to the need for higher quality standards within elastomer components.

Additionally, Next Breath, an Aptar Pharma business, will showcase its analytical services. The company has recently expanded to include development services for injectable delivery systems, with a core focus on extractables and leachables profiling. Attendees can learn more about how Next Breath can help to guide them through the quality requirement increases for component qualification, validation and regulatory compliance.

To connect with Aptar Pharma and meet our team of experts, register for the 2018 PDA Annual Meeting:

Photo: Doctor giving patient injection in volunteer clinic.

March 14, 2018

Aptar Pharma to Exhibit Key Innovative Drug Delivery Systems at P...

Aptar Pharma, a leading global solution provider of innovative drug delivery systems, is pleased to be a major exhibitor at Pharmapack 2018, taking place February 7 to 8 at Paris Expo, Porte de Versailles, France.

Pharmapack is Europe’s dedicated pharmaceutical packaging and drug delivery event. Welcoming over 400 exhibitors and more than 5,000 pharma and drug delivery professionals, Pharmapack provides invaluable insight into the latest trends, developments and regulatory changes impacting the industry.

Aptar Pharma experts will showcase the company’s extensive drug delivery device portfolio at Hall 7.1, Booth B24/B26. While at the booth, visitors are invited to explore the dedicated connectivity hub, which highlights the field of connected healthcare solutions, a growing technology megatrend.

 Further, three Aptar Pharma experts have been selected to present at the conference:

  • Gerallt Williams, Director Scientific Affairs, will lead a presentation titled, “Opportunities & Challenges of Drug Delivery via the Nasal Route,” on Thursday, February 8, at 10:00. 
  • Arnaud Fournier, Senior Business Project Manager – Injectables, will present a Learning Lab called “Setting the Standard for Film Coated Stoppers with an Unrivalled Reduction in Particulates,” on Wednesday, February 7, at 11:30.
  • Sai Shankar, Director Business Development – Connected Devices, will present a Learning Lab called “Driving Better Patient Outcomes with Connectivity,” on Wednesday, February 7, at 15:50. 

Aptar Pharma will also be a selected exhibitor on Pharmapack’s guided Innovation Tour on Thursday, February 8, at 10:30 at the Innovation Gallery.

To connect with Aptar Pharma and meet our team of experts, register for Pharmapack 2018 at:

For more information about Aptar Pharma’s presence at Pharmapack 2018, please click here to view the full press release.

January 10, 2018